Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies

Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies

US Patent 11912780 · Granted Feb 27, 2024

Estimated economic value: $3,529,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Radioconjugates targeting CD33 in the treatment of sarcomas2025
Radioconjugates directed to MHC-complexed antigens in cancer2025
Methods for treatment of patients with myelodysplastic syndromes2024
Anti-PD-L1-anti-TIM-3 bispecific antibodies2022
Checkpoint inhibitor bispecific antibodies2021
Anti-canine platelet derived growth factor receptor alpha antibody2020
Anti-PD-L1-anti-TIM-3 bispecific antibodies2019
PD-L1 antibodies2019
Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatmen2016
IGF-IR antagonists as adjuvants for treatment of prostate cancer2011
Fully human antibodies directed against the human insulin-like growth factor-1 r2011
Combination therapy for the treatment of acute leukemia and myelodysplastic synd2010